Table 3.

Absolute benefit increase and number needed to treat by comparator and study

Single Goals
	DURATION-4			DURATION-2			DURATION-3
Therapy	% Reaching Goal (N)	ABI (95% CI)	NNT (95% CI)	% Reaching Goal (N)	ABI (95% CI)	NNT (95% CI)	% Reaching Goal (N)	ABI (95% CI)	NNT (95% CI)
HbA1c <7.0%
ExQW	61.6%			58.6%			59.0%
	(237)			(157)			(222)
Met	54.8%	6.8%	15
	(239)	(-2%, 15%)	(7, ∞, -49)
Sita	41.4%	20.2%	5	27.7%	30.9%	4
	(152)	(10%, 30%)	(4, 10)	(155)	(20%, 41%)	(3, 5)
Pio	58.5%	3.0%	34	43.4%	15.2%	7
	(157)	(-7%, 13%)	(8, ∞, -15)	(159)	(4%, 26%)	(4, 24)
IG							46.5%	12.5%	8
							(215)	(3%, 22%)	(5, 32)
HbA1c ≤6.5%
ExQW	48.2%			38.8%			42.2%
	(247)			(160)			(232)
Met	36.2%	12.0%	9
	(243)	(3%, 20%)	(5, 31)
Sita	24.5%	23.7%	5	14.6%	24.2%	5
	(163)	(14%, 32%)	(4, 7)	(164)	(15%, 33%)	(3, 7)
Pio	40.9%	7.3%	14	26.1%	12.7	8
	(159)	(-3%, 17%)	(6, ∞, -38)	(165)	(3%, 23%)	(5, 40)
IG							28.1%	14.1%	8
							(221)	(5%, 23%)	(5, 19)
No Weight Gain
ExQW	72.6%			78.1%			84.1%
	(248)			(160)			(233)
Met	76.8%	-4.2%	-24
	(246)	(-12%, 3%)	(29, ∞, -9)
Sita	65.0%	7.6%	14	59.6%	18.5%	6
	(163)	(-1%, 17%)	(6, ∞, -69)	(166)	(8%, 28%)	(4, 12)
Pio	36.8%	35.8%	3	24.2%	53.9%	2
	(163)	(26%, 45%)	(3, 4)	(165)	(44%, 62%)	(2, 3)
IG							33.2%	50.9%	2
							(223)	(43%, 58%)	(2, 3)
Any Weight Loss
ExQW	68.5%			76.9%			79.0%
	(248)			(160)			(233)
Met	72.8%	-4.3%	-24
	(246)	(-12%, 4%)	(27, ∞, -9)
Sita	55.9%	12.7%	8	59.0%	17.9%	6
	(163)	(3%, 22%)	(5, 32)	(166)	(8%, 27%)	(4, 13)
Pio	33.1%	35.4%	3	21.2%	55.7%	2
	(163)	(26%, 44%)	(3, 4)	(165)	(46%, 64%)	(2, 3)
IG							30.5%	48.5%	3
							(223)	(40%, 56%)	(2, 3)
No Major/Minor Hypoglycemia
ExQW	98.0%			98.8%			88.4%
	(248)			(160)			(233)
Met	100.0%	-2.0%	-50
	(246)	(-5%, 0%)	(∞, -22)
Sita	100.0%	-2.0%	-50	97.0%	1.8%	56
	(163)	(-5%, 1%)	(175, ∞, -22)	(166)	(-2%, 6%)	(17, ∞, -56)
Pio	100.0%	-2.0%	-50	98.8%	0	N/A
	(163)	(-5%, 1%)	(175, ∞, -22)	(165)	(-3%, 3%)
IG							69.5%	18.9%	6
							(223)	(12%, 26%)	(4, 9)
SBP<130 mm Hg
ExQW	39.7%			56.9%			25.3%
	(126)			(58)			(154)
Met	25.0%	14.7%	7
	(124)	(3%, 26%)	(4, 32)
Sita	31.2%	8.5%	12	34.8%	22.1%	5
	(93)	(-4%, 21%)	(5, ∞, -23)	(66)	(5%, 38%)	(3, 22)
Pio	32.2%	7.5%	14	39.1%	17.8%	6
	(87)	(-6%, 20%)	(5, ∞, -18)	(69)	(0%, 34%)	(3, 244)
IG							21.3%	4.0%	25
							(136)	(-6%, 14%)	(8, ∞, -17)
FBG <6.99 mmol/L (<126 mg/dL)
ExQW	47.0%			54.9%			38.6%
	(219)			(122)			(215)
Met	34.1%	12.9%	8
	(217)	(4%, 22%)	(5, 27)
Sita	20.8%	26.2%	4	27.4%	27.5%	4
	(144)	(16%, 35%)	(3, 7)	(135)	(16%, 38%)	(3, 7)
Pio	48.3%	-1.3%	-77	44.5%	10.4%	10
	(145)	(-12%, 9%)	(11, ∞, -9)	(137)	(-2%, 22%)	(5, ∞, -57)
IG							51.5%	-12.9%	-8
							(200)	(-22%, -3%)	(-5, -30)
LDL <2.59 mmol/L (100 mg/dL)
ExQW	20.2%			29.8%			32.3%
	(168)			(84)			(130)
Met	23.1%	-2.9%	-35
	(160)	(-12%, 6%)	(17, ∞, -9)
Sita	13.8%	6.4%	16	21.6%	8.2%	13
	(109)	(-3%, 15%)	(7, ∞, -33)	(97)	(-4%, 21%)	(5, ∞, -22)
Pio	13.0%	7.2%	14	19.4%	10.4%	10
	(115)	(-2%, 16%)	(7, ∞, -52)	(103)	(-2%, 23%)	(5, ∞, -53)
IG							15.3%	17.0%	6
							(124)	(7%, 27%)	(4, 15)
Composite Goals
HbA1c <7.0%, No Weight Gain, No Hypoglycemia
ExQW	48.4%			48.1%			46.8%
	(248)			(160)			(233)
Met	48.0%	0.4%	250
	(246)	(-8%, 9%)	(11, ∞, -12)
Sita	34.4%	14.0%	8	22.3	25.8%	4
	(163)	(4%, 23%)	(5, 24)	(166)	(16%, 35%)	(3, 7)
Pio	21.5%	26.9%	4	9.7%	38.4%	3
	(163)	(18%, 35%)	(3, 6)	(165)	(29%, 47%)	(3, 4)
IG							13.0%	33.8%	3
							(223)	(26%, 41%)	(3, 4)
HbA1c ≤6.5%, No Weight Gain, No Hypoglycemia
ExQW	39.1%			32.5%			30.5%
	(248)			(160)			(233)
Met	32.9%	6.2%	17
	(246)	(-2%, 15%)	(7, ∞, -44)
Sita	19.6%	19.5%	6	12.0%	20.5%	5
	(163)	(11%, 28%)	(4, 10)	(166)	(12%, 29%)	(4, 9)
Pio	17.2%	21.9%	5	5.5%	27.0%	4
	(163)	(13%, 30%)	(4, 8)	(165)	(19%, 35%)	(3, 6)
IG							9.4%	21.1%	5
							(223)	(14%, 28%)	(4, 8)
HbA1c<7%, SBP <130 mm Hg, LDL <2.59 mmol/L
ExQW	15.0%			22.6%			17.7%
	(246)			(159)			(231)
Met	13.4%	1.6%	63
	(246)	(-5%, 8%)	(13, ∞, -22)
Sita	5.0%	10.0%	10	11.6%	11.0%	10
	(160)	(4%, 16%)	(7, 25)	(164)	(3%, 19%)	(6, 36)
Pio	8.7%	6.3%	16	14.6%	8.0%	13
	(161)	(0%, 12%)	(9, ∞, -285)	(164)	(-1%, 16%)	(7, ∞, -197)
IG							10.3%	7.4%	14
							(223)	(1%, 14%)	(8, 101)
HbA1c ≤6.5%, SBP<130 mm Hg, LDL <2.59 mmol/L
ExQW	12.9%			16.9%			12.9%
	(248)			(160)			(232)
Met	7.7%	5.2%	20
	(246)	(0%, 11%)	(10, ∞, -490)
Sita	4.3%	8.6%	12	6.1%	10.8%	10
	(163)	(3%, 14%)	(8, 34)	(165)	(4%, 18%)	(6, 26)
Pio	6.2%	6.7%	15	9.1%	7.8%	13
	(161)	(1%, 12%)	(9, 152)	(165)	(0%, 15%)	(7, 220 )
IG							5.8%	7.1%	15
							(223)	(2%, 13%)	(8, 58)

ABI, Absolute Benefit Increase; NNT, number needed to treat;

NNT compares ExQW with indicated comparator; an infinity limit (∞) is shown for the 95% CI of the NNT if the 95% CI of the ABI contains zero;

N refers to subjects not at goal at baseline.